Last updated: February 25, 2026
What is NDC 65862-0829?
NDC 65862-0829 refers to a specific drug within the National Drug Code (NDC) database, identifying a branded or generic pharmaceutical product. Details typically include drug name, dosage, form, route, and packaging. Based on current market data, this NDC corresponds to atezolizumab (brand: Tecentriq), a programmed death-ligand 1 (PD-L1) inhibitor used in oncology treatments.
Market Position and Competitors
Indications and Market Penetration
Atezolizumab is approved for multiple indications:
- Non-small cell lung cancer (NSCLC)
- Triple-negative breast cancer (TNBC)
- Urothelial carcinoma
It is marketed primarily by Roche. Its market share varies across indications, with significant footholds in first-line NSCLC and metastatic bladder cancer.
Competitors
Main competitors include:
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Durvalumab (Imfinzi)
These PD-1 and PD-L1 inhibitors are part of a broader immune checkpoint inhibitor class with overlapping indications.
Market Size (2022–2025)
The global oncology immunotherapy market was valued at approximately USD 22 billion in 2022. Projected compound annual growth rate (CAGR) is around 12%. Atezolizumab holds an estimated 20–25% share within the PD-L1 inhibitor segment.
| Year |
Market Size (USD billion) |
Atezolizumab Market Share (%) |
Estimated Revenue (USD billion) |
| 2022 |
22 |
20 |
4.4 |
| 2023 |
24.6 |
20.5 |
5.0 |
| 2024 |
27.6 |
21 |
5.8 |
| 2025 |
30.9 |
21.5 |
6.7 |
Note: These projections include growth driven by expanded indications and label expansions.
Pricing Analysis
Current Pricing Landscape
The wholesale acquisition cost (WAC) per 1200 mg dose of atezolizumab is approximately USD 13,000, with actual prices to payers often exceeding this after negotiations.
Average Selling Price (ASP)
ASP for atezolizumab in 2022 was estimated at USD 12,500 per 1200 mg dose, based on market reports and insurance reimbursement data.
Revenue Drivers
Pricing dynamics are influenced by:
- Indication exclusivity: Continued patent protections and label exclusivity shape pricing power.
- Market access policies: Payer negotiations, tiered formularies, and biosimilar entry affect net prices.
- Successful clinical trials: Positive results can justify higher list prices.
Biosimilar Impact
The first biosimilar to atezolizumab is anticipated in 2026–2027, with a potential 20–30% reduction in price within two years of market entry due to price competition.
Price Projections (2023–2025)
Assuming moderate market growth, patent protections maintained, and no immediate biosimilar competition, prices are projected as follows:
| Year |
Estimated ASP per 1200 mg Dose (USD) |
Rationale |
| 2023 |
12,500 |
Stable; slight inflation and payer negotiations ongoing |
| 2024 |
12,250 |
Slight price pressure from increasing biosimilar presence |
| 2025 |
11,750 |
Biosimilar entry approaching; further price reductions |
Regulatory and Patent Considerations
- Patent expiry expected around 2028 in key markets.
- Ongoing label expansions may lead to additional patent and exclusivity protections.
- Regulatory landscape favors strong patent protections for brand products.
Key Takeaways
- Atezolizumab remains a significant player in PD-L1 inhibitor oncology therapy.
- Market share is stabilized by a broad indication portfolio and ongoing clinical trial success.
- Prices are expected to decline modestly over the next two years, accelerated by biosimilar competition.
- The total market is projected to grow at a CAGR of approximately 12%, reaching USD 30.9 billion by 2025.
- Patent protection and regulation will influence pricing trends until at least 2028.
FAQs
How does the price of atezolizumab compare to similar drugs?
The ASP per dose of atezolizumab (USD 12,500) is comparable with other PD-L1 inhibitors such as pembrolizumab and nivolumab, which range between USD 10,000 and USD 14,000 per dose, depending on indication and dosage.
What factors influence future price reductions?
Biosimilar entry, increased market competition, payer negotiations, and potential patent loss are primary factors.
When are biosimilars expected to enter the market?
The first biosimilar for atezolizumab is projected to launch in 2026–2027, with initial price reductions of 20–30%.
What is the expected growth for the PD-L1 inhibitor segment?
Segment growth is projected at CAGR of approximately 12% through 2025, driven by expanding indications and clinical research.
How do regulatory changes impact pricing?
Regulatory policies aimed at reducing healthcare costs, such as price controls or favoring biosimilars, can accelerate price declines and market share shifts.
References
[1] IQVIA. (2023). Global Oncology Market Report.
[2] FDA. (2022). Highlights of Prescribing Information for Tecentriq (atezolizumab).
[3] EvaluatePharma. (2023). Oncology Immunotherapy Market Forecast.
[4] SSR Health. (2022). U.S. Biosimilar and Biologic Pricing Data.
[5] European Medicines Agency. (2022). Patent lifecycle and regulatory framework for immune checkpoint inhibitors.
